<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00097929</url>
  </required_header>
  <id_info>
    <org_study_id>0683-013</org_study_id>
    <secondary_id>MK0683-013</secondary_id>
    <secondary_id>2004_029</secondary_id>
    <nct_id>NCT00097929</nct_id>
    <nct_alias>NCT00124631</nct_alias>
  </id_info>
  <brief_title>An Investigational Drug Study With Suberoylanilide Hydroxamic Acid in Relapsed Diffuse Large B-cell Lymphoma (0683-013)</brief_title>
  <official_title>A Phase II Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      A study to determine the safety, tolerability, and anti-tumor effectiveness of an oral
      investigational drug in the treatment of relapsed diffuse large B-cell lymphoma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2005</start_date>
  <completion_date type="Actual">July 31, 2006</completion_date>
  <primary_completion_date type="Actual">July 31, 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate based on FDG-PET and CT scan findings.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response duration, Progression-free survival, Time to progression, Time to response, 3-Month and 6-month progression free survival.</measure>
  </secondary_outcome>
  <enrollment type="Actual">18</enrollment>
  <condition>B-cell Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient must be 18 years or older with relapsed Diffuse Large B-cell Lymphoma (DLBCL).

          -  Stable disease or better for at least 3 months on most recent treatment

          -  Have not received any chemotherapy, radiation therapy, major surgery, or any other
             investigational therapy for at least 4 weeks prior to entry in this study

          -  Adequate blood testing, liver, and kidney function as required by the study.

          -  Eligible subjects will allow tissue samples to be examined and stored.

        Exclusion Criteria:

          -  Patient has been treated with other investigational agents with a similar anti-tumor
             mechanism.

          -  Patient should not have failed more than 3 prior treatment regimens.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <reference>
    <citation>Crump M, Coiffier B, Jacobsen ED, Sun L, Ricker JL, Xie H, Frankel SR, Randolph SS, Cheson BD. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann Oncol. 2008 May;19(5):964-9. doi: 10.1093/annonc/mdn031. Epub 2008 Feb 21.</citation>
    <PMID>18296419</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2004</study_first_submitted>
  <study_first_submitted_qc>December 1, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2004</study_first_posted>
  <last_update_submitted>April 5, 2017</last_update_submitted>
  <last_update_submitted_qc>April 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapsed Diffuse Large B-cell Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vorinostat</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis Links</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/policies-perspectives.html</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

